Engineering strategies for generating hypoimmunogenic cells with high clinical and commercial value
Allogeneic cell therapy, where patients receive cells from a “nonself donor”, is superior to autologous cell therapy using a patient's own cells. Autologous cells are higher quality, have a lower cost of manufacturing, and higher scalability for production. However, allogeneic therapy poses a considerable challenge because of the immune response mounted by a mismatch between donor and recipient
View the full peer-reviewed scientific paper at Future Medicine.